miami tirzepatide class action What Is for Weight Loss? Resource Guide GLP-1 medications in

At its core, these lawsuits allege that Novo Nordisk knew, or reasonably should have known, that semaglutide carries a significant risk of causing severe gastrointestinal conditions, including gastroparesis, ileus, and intestinal obstruction , and that the company failed to adequately warn patients and healthcare providers about these risks on the drug's official label

Certification Risks: Non-disclosure can result in suspension or revocation

Increases in oxygen demand can worsen myocardial ischemia in some clinical settings (e.g

This compares to $969 monthly for Ozempic and $1,349 for Wegovy, representing savings of $770 to $1,150 monthly